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alone or improvement in PA saturations alone. Likewise a fall in
PAEDP and poor improvement in saturations leads to higher post-
operative residual PAH and longer ICU ventilator need and need
for milrinone to counter postoperative residual PAH.
Comparison of ambrisentan with sildenafil in
congenital heart disease with irreversible
pulmonary artery hypertension
P.M. Raut, S. Prabhu, N.S. Waghmare, S. Shivpuje, N.O. Bansal
Sir J.J.Group of hospitals, Mumbai, India
Background: The pathogenesis of PAH involves endothelial
dysfunction characterised by over-expression of vasoconstrictors
such as endothelin-1 (ET-1) and thromboxane A2. Endothelin re-
ceptor antagonists (ERAs) are a class of potent vasodilators and
antimitotic substances. Aims&Objectives - To assess the efficacy of
endothelin receptor antagonists (ERAs) Ambrisentanin the treat-
ment of patients with PAH secondary to congenital heart disease.
Methods: It is a retrospective observational study, carried out at
single tertiary care center. Patient of acyanotic congenital heart
diseases (e.g.VSD, PDA, AV canal defect) admitted in cardiology
department, found to have irreversible pulmonary hypertension
on cardiac catheterization were enrolled in study. A total of 42
patients were enrolled in the study, 24 patients had received 10
mg of ambrisentan and remaining group 20 patient had received
sildenafil at maximum tolerated dose for at least 6 months.
Primary outcomes were exercise capacity (a six-minute walk
test (6MWD)) and World Health Organization (WHO) functional
class or New York Heart Association (NYHA) functional class.
Secondary outcome- Adverse events (for example, hepatic
toxicity).
Results: An increase in the 6MWD was reported in the ambri-
sentan group . Increases in the 6MWDat 24weekswas 51meters in
Ambrisentan group compared to 20 meters in sildenafil
group.(95% CI 27e76; P , 0.001). Patient enrolled in the study were
prominently WHO functional classification II (29%) and III (65%).
Study demonstrated a significant improvement in WHO func-
tional classification for patients receiving ambrisentan as
compared with sildenafil (P ¼ 0.036). Of the patients receiving
ambrisentan, 2 (9.7%) discontinued because of adverse events (
gastroenteritis,headache/face edema [n¼1 for each].Side effect of
ambrisentanwas found to be headache 2 (9.0%), peripheral edema
4(18.18%).No evidence of hepatotoxicity like elevated liver en-
zymes, bilirubin in ambrisentan group.
Conclusion: Study demonstrate the efficacy and safety of ambri-
sentan in the treatment of patients with symptomatic PAH. The
favorable efficacy-to-safety profile of ambrisentan may offer po-
tential advantages over the currently approved treatment options.
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Background: Ventricular septal defect (VSD) is the most common
congenital heart defect at birth, as well as one of the common
heart defects in adult age group. Repair of ventricular septal defect
(VSD) has been historically performed surgically. However,
percutaneous VSD closure is also feasible and the frequency has
increased given the desire of young patients to avoid surgery.
Standard treatment of VSD is open surgery, which is widely per-
formed with but still carries risks, such as complete atrioven-
tricularblock , residual shunt, postpericardiotomy syndrome, and
wound infection. Transcatheter VSD device closure is a treatment
option for isolated uncomplicated muscular VSDs, and for mem-
branous VSDs, in selected patients with suitable anatomy.
Appropriate anatomy for transcatheter closure includes a VSD
location remote from the tricuspid and aortic valves with an
adequate rim of tissue.
Here we are presenting our experience about percutaneous VSD
device closure or attempted VSD device closure in 12 patients at
tertiary care centre.
Methods: Between June 2013 and July 2014 patients undergoing
percutaneousVSD device closure or attempted VSD device closure
were studied retrospectively. All patients underwent detailed
conventional two dimensional and colour Doppler transthoracic
echocardiography to study the type of VSD, shunt across the VSD ,
length of aortic rim and pulmonary hypertension.VSD size was
confirmed angiographically and device closure was done under
general anesthesia with TEE guidance according to standard
protocol. During immediate postoperative period, rhythm and
position was monitored by doing ECG and TTE respectively. Pa-
tients were given weight based aspirin and clopidogrel for 6
months. Patients were followed up on outpatient basis every 6
months for 1 yr and then every year and TTE was done during
each visit.
Result: There were total 12 patients out of which successful device
closure was done in 10 patients. The average age of patient was 6.9
yrs (ranges 2.5 to 18 yrs). The 5(41.6%) patients were female and 7
(58.3%) weremale. Themedian size of VSDwas 5.3mm (ranges 2.3
to 16 mm) one (8.3%) patient had two VSD. Average size of device
used was 7.1 mm .procedure related complication occurred in 4
patients. One (8.3%) patient had CHB after releasing of LV disc
hence procedure was abandoned. One (8.3%) patient had embo-
lization of device in the aorta which was successfully retrieved by
transcutaneous route. No patient had postprocedure death.No
Patients had postoperative rhythm disturbances. All patients
were discharged two days after procedure. All patients were
follow up at six month and 1 year by ECG and transthoracic
echocardiography.
Conclusion: In experienced hands, transcatheter VSD closure can
be performed safely and successfully with low morbidity and-
mortality. Transcatheter approach provides a less-invasive alter-
native that may become the first choice in selected VSD patients.
Experience with large ostium secundum atrial
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D.K. Ware, N.O. Bansal, S. Prabhu, S. Shivapuje
GMC and J.J. Hospital, Mumbai, India
Background: Small ASD are routinely closed by device.Larger ASD
by device closure is problematic. But, in these defects also, device
closure has high success. We present our experience of device
closure of ASD measuring >25 mm.
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